Voyager Therapeutics, Inc.
VYGR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001640266
No open-market purchases or sales by Voyager Therapeutics, Inc. insiders were filed in the last 90 days; 135 institutions reported holding it in 13F filings for Q2 2026, worth $122.7M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Voyager Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Voyager Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Scangos George A | Director | – | Jun 11, 2026 | 1 |
| Geraghty James A | Director | – | Jun 11, 2026 | 1 |
| Pierce Glenn | Director | 16,788 | Jun 11, 2026 | 1 |
| Higgins Michael J | Director | 31,314 | Jun 11, 2026 | 1 |
| Mackey Catherine J | Director | – | Jun 11, 2026 | 1 |
| Hyman Steven | Director | – | Jun 11, 2026 | 1 |
| Colon Grace | Director | – | Jun 11, 2026 | 1 |
| Vitale Nancy | Director | – | Jun 11, 2026 | 1 |
| Onyia Jude | Director | – | Jun 11, 2026 | 1 |
| Sandrock Alfred | President and CEO | 472,549 | Apr 3, 2026 | 5 |
| Shiferman Gregory L. | SVP and General Counsel | 50,000 | Apr 3, 2026 | 2 |
| Jorgensen Nathan D. | Chief Financial Officer | 151,416 | Feb 26, 2026 | 3 |
| Swartz Robin | COO & CBO | 199,738 | Feb 26, 2026 | 4 |
| Carter Todd Alfred | Chief Scientific Officer | 145,718 | Feb 26, 2026 | 4 |
| Ferguson Toby | Chief Medical Officer | 183,914 | Feb 10, 2026 | 1 |
| Fahey Sandell Jacquelyn | Chief Legal Officer | 123,143 | Feb 24, 2025 | 0 |
| Pfreundschuh Peter P. | Chief Financial Officer | 175,669 | Feb 22, 2024 | 0 |
| Hesslein Robert W. | Senior VP & General Counsel | 102,200 | Mar 22, 2023 | 0 |
| Neurocrine Biosciences Inc | 10% Owner | 8,575,316 | Feb 24, 2023 | 0 |
| Tepper Robert I | 10% Owner | 3,185,291 | Feb 6, 2023 | 0 |
| Third Rock Ventures III, L.P. | 10% Owner | 3,185,291 | Feb 6, 2023 | 0 |
| TRV GP III, LLC | 10% Owner | 3,185,291 | Feb 6, 2023 | 0 |
| Third Rock Ventures GP III, L.P. | 10% Owner | 3,185,291 | Feb 6, 2023 | 0 |
| EcoR1 Capital, LLC | 10% Owner | 3,851,507Indirect | Jan 11, 2023 | 0 |
| Burek Julie | VP, Finance | 52,458 | Mar 23, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 15, 2025 (view filing) | Jan 14 | 1 day | Carter Todd AlfredChief Scientific Officer | SSale | −1.19K | $5.13 | −$6.11K | −1.4%86.4K after | |
| Jan 15, 2025 (view filing) | Jan 14 | 1 day | Swartz RobinCOO & CBO | SSale | −3.09K | $5.09 | −$15.7K | −2.7%109.2K after | |
| Feb 12, 2025 (view filing) | Feb 11 | 1 day | Fahey Sandell JacquelynChief Legal Officer | SSale | −4.36K | $4.45 | −$19.4K | −5.1%81.6K after | |
| Feb 12, 2025 (view filing) | Feb 11 | 1 day | Sandrock AlfredPresident & CEO | SSale | −16.6K | $4.45 | −$74.1K | −5.1%308.5K after | |
| Feb 12, 2025 (view filing) | Feb 11 | 1 day | Swartz RobinCOO & CBO | SSale | −6.95K | $4.45 | −$30.9K | −6.4%102.3K after | |
| Feb 12, 2025 (view filing) | Feb 11 | 1 day | Carter Todd AlfredChief Scientific Officer | SSale | −5.41K | $4.45 | −$24.1K | −6.3%81.0K after | |
| Feb 24, 2025 (view filing) | Feb 20 | 4 days | Swartz RobinCOO & CBO | SSale | −3.89K | $4.25 | −$16.5K | −3.8%98.4K after | |
| Feb 24, 2025 (view filing) | Feb 20 | 4 days | Sandrock AlfredPresident and CEO | SSale | −11.7K | $4.24 | −$49.6K | −3.8%296.8K after | |
| Feb 24, 2025 (view filing) | Feb 20 | 4 days | Carter Todd AlfredChief Scientific Officer | SSale | −3.31K | $4.26 | −$14.1K | −4.1%77.7K after | |
| Apr 4, 2025 (view filing) | Apr 2 | 2 days | Sandrock AlfredPresident and CEO | SSale | −10.9K | $3.43 | −$37.3K | −2.5%430.9K after | |
| Apr 4, 2025 (view filing) | Apr 2 | 2 days | Ferguson TobyChief Medical Officer | SSale | −10.1K | $3.43 | −$34.6K | −6.0%157.9K after | |
| Aug 20, 2025 (view filing) | Aug 18 | 2 days | Ferguson TobyChief Medical Officer | SSale | −19.0K | $3.73 | −$70.9K | −12.0%138.9K after | |
| Oct 7, 2025 (view filing) | Oct 3 | 4 days | Jorgensen Nathan D.Chief Financial Officer | SSale | −7.67K | $4.78 | −$36.6K | −5.8%123.8K after | 10b5-1 |
| Feb 11, 2026 (view filing) | Feb 10 | 1 day | Carter Todd AlfredChief Scientific Officer | SSale | −3.52K | $3.85 | −$13.6K | −2.2%153.2K after | |
| Feb 11, 2026 (view filing) | Feb 10 | 1 day | Sandrock AlfredPresident and CEO | SSale | −12.2K | $3.78 | −$46.1K | −2.3%510.0K after | |
| Feb 11, 2026 (view filing) | Feb 10 | 1 day | Swartz RobinCOO & CBO | SSale | −4.57K | $3.85 | −$17.6K | −2.1%210.1K after | |
| Feb 20, 2026 (view filing) | Feb 18 | 2 days | Sandrock AlfredPresident and CEO | SSale | −11.7K | $3.41 | −$40.0K | −2.3%498.3K after | 10b5-1 |
| Feb 20, 2026 (view filing) | Feb 18 | 2 days | Carter Todd AlfredChief Scientific Officer | SSale | −3.30K | $3.44 | −$11.4K | −2.2%149.9K after | 10b5-1 |
| Feb 20, 2026 (view filing) | Feb 18 | 2 days | Swartz RobinCOO & CBO | SSale | −3.88K | $3.44 | −$13.4K | −1.8%206.2K after | 10b5-1 |
| Feb 26, 2026 (view filing) | Feb 24 | 2 days | Carter Todd AlfredChief Scientific Officer | SSale | −4.17K | $3.76 | −$15.7K | −2.8%145.7K after | 10b5-1 |
| Feb 26, 2026 (view filing) | Feb 24 | 2 days | Jorgensen Nathan D.Chief Financial Officer | SSale | −4.67K | $3.77 | −$17.6K | −3.0%151.4K after | 10b5-1 |
| Feb 26, 2026 (view filing) | Feb 24 | 2 days | Sandrock AlfredPresident and CEO | SSale | −14.2K | $3.79 | −$53.8K | −2.8%484.1K after | 10b5-1 |
| Feb 26, 2026 (view filing) | Feb 24 | 2 days | Swartz RobinCOO & CBO | SSale | −6.46K | $3.77 | −$24.3K | −3.1%199.7K after | 10b5-1 |
| Apr 3, 2026 (view filing) | Apr 2 | 1 day | Sandrock AlfredPresident and CEO | SSale | −11.5K | $3.87 | −$44.5K | −2.4%472.5K after | 10b5-1 |